Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Objective: Patients with diabetes mellitus are at increased risk for hepatitis B virus (HBV) infection and its complications. HBV vaccination is recommended for adults with diabetes in the United States and other countries. However, few studies have assessed safety and immunogenicity of hepatitis B vaccine in such patients. We assessed the safety and immunogenicity of recombinant hepatitis B vaccine in subjects with and without diabetes mellitus. METHODS: Prospective, multi-country controlled study in 21 centers ( www.clinicaltrials.gov NCT01627340). Four hundred and sixteen participants with Type-2 diabetes and 258 controls matched for age and body mass index (BMI) (2:1 ratio) received 3-doses of HBV vaccine (Engerix-B™, GSK Vaccines, Belgium) according to a 0, 1, 6 months schedule. Antibodies were measured against HBV surface antigen and expressed as seroprotection rates (anti-HBs ≥10mIU/mL) and geometric mean concentration (GMC). RESULTS: , respectively. Seroprotection rates (GMCs) one month post-dose-3 were 75.4% (147.6 mIU/mL) and 82.0% (384.2 mIU/mL) in patients with diabetes and controls, respectively. Age-stratified seroprotection rates for patients with diabetes were 88.5% (20-39 years), 81.2% (40-49 years), 83.2% (50-59 years), and 58.2% (≥60 years). The overall safety profile of hepatitis B vaccine was similar between groups. CONCLUSIONS: Hepatitis B vaccine is immunogenic in patients with diabetes and has a similar safety profile to vaccination in healthy controls. Because increasing age was generally associated with a reduction in seroprotection rates, hepatitis B vaccine should be administered as soon as possible after the diagnosis of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“meta-analyses have not uncovered increased risk for thyroid cancer with GLP-1 RAs or DPP-4 inhibitors.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1813]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, there is no evidence that incretin-based therapies increase risk for medullary thyroid carcinoma in humans.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1813]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Cui, W., Sun, C.-M., Deng, B., & Liu, P. (2013) · Gene · doi:10.1016/j.gene.2013.04.065 · Cited by 23 · cited 1×
“Regression models used age, BMI, eGFR, and HbA1c as continuous factors, and diabetes, gender and White-Caucasian versus Other ancestry as categorical factors: ancestry was included in the model because of evidence of reduced responses to hepatitis B vaccine in some populations.(29,30) A logistic regression was used to…”
MethodRetractedToprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“73m(2) as estimated through the Modification of Diet in Renal Disease,(25) or the Chronic Kidney Disease Epidemiology Collaboration equation.(26)”
MethodLevey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s062 · Cited by 5,491
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851 · cited 1×
“Exploratory group comparisons were performed using the asymptotic standardized 95% CIs for the group difference (Control Group-Diabetes Group) in seroprotection rates.(28) The 95% CI for the adjusted GMC group ratio (Diabetes Group divided by Control Group) was computed using an analysis of variance (ANOVA) model on t…”
MethodCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745 · cited 3×
“individuals with an antiHBs antibody titer 10mIU/mL are seroprotected.(20,21) Secondary objectives were to assess anti-HBs antibody concentrations”
BackgroundMethodResultAntibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064
Gruver, A., Hudson, L., & Sempowski, G. (2007) · The Journal of Pathology · doi:10.1002/path.2104 · Cited by 834
Research works printed but not linked: 3
- Farkas K, Jermendy G Transmission of hepatitis B infection during home blood glucose monitoring. Diabet Med 1997; 14(3): 263; http://dx.doi.org/ 10.1002/(SICI)1096-9136(199703)14:3%3c263::AID-DIA342%3e3.0.CO;2-R 9088777 · doi:10.1002/(sici)1096-9136(199703)14:3<263::aid-dia342>3.0.co;2-r
- 10.1002/(sici)1096-9136(199703)14:3%3c263::aid-dia342%3e3.0.co;2-r · doi:10.1002/(sici)1096-9136(199703)14:3<263::aid-dia342>3.0.co;2-r
- Public Health Agency of Canada Canadian Immunization Guide. Part 4 Active Vaccines. Hepatitis B Vaccine [article online]. Ottowa: 2015, Public Health Agency of Canada. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-hepb-eng.php [Accessed 20 2 2015].
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
The double burden of diabetes and global infection in low and middle-income countries
Dunachie, S., & Chamnan, P. (2019) · Transactions of The Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/try124 · Cited by 194
“Most studies support adequate induction of antibodies in response to licenced antibody-inducing vaccines in people with diabetes [91] [92] [93] .”
BackgroundJackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.038 · Cited by 197
Pathology of Diabetes-Induced Immune Dysfunction
Alexander, M., Cho, E., Gliozheni, E., Salem, Y., Cheung, J., & Ichii, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137105 · Cited by 117
van den Ende, C., Marano, C., van Ahee, A., Bunge, E. M., & Moerlooze, L. D. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1338568 · Cited by 68
“Subjects were less likely to achieve seroprotection if they had an increased BMI and if they were of older age [69].”
BackgroundResultInfluential
Metadata
- Authors
- Van Der Meeren, O., Peterson, J. T., Dionne, M., Beasley, R., Ebeling, P. R., Ferguson, M., Nissen, M. D., Rheault, P., Simpson, R. W., De Ridder, M., Crasta, P. D., Miller, J. M., & Trofa, A. F.
- Affiliations
- Centre hospitalier universitaire de Québec (CA)
- Medical Research Institute of New Zealand (NZ)
- Monash University (AU)
- The University of Queensland (AU)
- Eastern Health (AU)
- GlaxoSmithKline (India) (IN)
- GlaxoSmithKline (United States) (US)
- Venue
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2016-04-28
- Volume
- 12
- Issue
- 8
- Pages
- 2197-2203
- ISSN
- 2164-5515 (ISSN-L)
- 2164-554X
- PMC
- PMC4994745
- OpenAlex
- W2345116174
- Cited by
- 34
- References
- 29
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 3 · 2018: 1 · 2017: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Human Vaccines & Immunotherapeutics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- Monash University Research Portal (Monash University) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc)
- Funders
- GlaxoSmithKline
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Keywords
- hepatitis B vaccination, type 2 diabetes, recombinant hepatitis B vaccine, Engerix-B, vaccine immunogenicity, vaccine safety, seroprotection rate, anti-HBs antibodies
- MeSH terms
- Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Female, Hepatitis B Antibodies, Hepatitis B Surface Antigens, Humans, Male, Middle Aged, Prospective Studies, Vaccines, Synthetic, Hepatitis B Vaccines, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. https://app.cochat.ai/papers/10.1080/21645515.2016.1164362
- The paper
- Van Der Meeren, O., Peterson, J. T., Dionne, M., Beasley, R., Ebeling, P. R., Ferguson, M., Nissen, M. D., Rheault, P., Simpson, R. W., De Ridder, M., Crasta, P. D., Miller, J. M., & Trofa, A. F. (2016). Prospective clinical trial of hepatitis B vaccination in adults with and without type-2 diabetes mellitus. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2016.1164362
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.